Rep. Gilbert Ray Cisneros, Jr. Purchases Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH)

Representative Gilbert Ray Cisneros, Jr. (D-California) recently bought shares of Lantheus Holdings, Inc. (NASDAQ:LNTH). In a filing disclosed on February 11th, the Representative disclosed that they had bought between $1,001 and $15,000 in Lantheus stock on January 28th. The trade occurred in the Representative's "150 MAIN STREET TRUST > BANK OF AMERICA" account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Sold $1,001 - $15,000 in shares of ICF International NASDAQ: ICFI on 2/3/2025.
• Purchased $15,001 - $50,000 in shares of CACI International NYSE: CACI on 1/31/2025.
• Purchased $50,001 - $100,000 in shares of Hawaiian Electric Industries NYSE: HE on 1/31/2025.
• Sold $1,001 - $15,000 in shares of Broadcom NASDAQ: AVGO on 1/30/2025.
• Purchased $1,001 - $15,000 in shares of Intuitive Surgical NASDAQ: ISRG on 1/30/2025.
• Purchased $1,001 - $15,000 in shares of Agios Pharmaceuticals NASDAQ: AGIO on 1/29/2025.
• Purchased $1,001 - $15,000 in shares of SpringWorks Therapeutics NASDAQ: SWTX on 1/29/2025.
• Purchased $1,001 - $15,000 in shares of Paragon 28 NYSE: FNA on 1/29/2025.
• Purchased $1,001 - $15,000 in shares of U.S. Physical Therapy NYSE: USPH on 1/29/2025.
• Purchased $1,001 - $15,000 in shares of Crinetics Pharmaceuticals NASDAQ: CRNX on 1/29/2025.

Lantheus Stock Down 2.5 %

Shares of LNTH traded down $2.02 during mid-day trading on Friday, hitting $79.94. 737,336 shares of the company's stock traded hands, compared to its average volume of 709,331. Lantheus Holdings, Inc. has a 1 year low of $56.06 and a 1 year high of $126.89. The firm has a market capitalization of $5.56 billion, a P/E ratio of 13.30 and a beta of 0.44. The business's 50-day moving average price is $91.43 and its 200-day moving average price is $97.66.

Remove Ads

Wall Street Analysts Forecast Growth

LNTH has been the topic of several research analyst reports. StockNews.com cut Lantheus from a "buy" rating to a "hold" rating in a research note on Thursday, November 21st. Truist Financial reaffirmed a "buy" rating and issued a $120.00 price target (down from $135.00) on shares of Lantheus in a research note on Friday, November 8th. JMP Securities reaffirmed a "market outperform" rating and issued a $112.00 price target on shares of Lantheus in a research note on Tuesday, January 14th. Finally, The Goldman Sachs Group began coverage on Lantheus in a research note on Wednesday, December 18th. They issued a "buy" rating and a $143.00 price target on the stock. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $131.86.

Insider Activity

In other news, Director James H. Thrall sold 1,000 shares of the company's stock in a transaction on Wednesday, January 15th. The stock was sold at an average price of $94.76, for a total transaction of $94,760.00. Following the transaction, the director now directly owns 33,207 shares of the company's stock, valued at $3,146,695.32. This represents a 2.92 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Corporate insiders own 1.50% of the company's stock.

Institutional Investors Weigh In On Lantheus

A number of institutional investors have recently modified their holdings of LNTH. T. Rowe Price Investment Management Inc. grew its stake in shares of Lantheus by 40.5% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 1,509,332 shares of the medical equipment provider's stock worth $135,025,000 after acquiring an additional 435,445 shares during the last quarter. Raymond James Financial Inc. purchased a new stake in shares of Lantheus in the fourth quarter worth $36,183,000. Groupama Asset Managment purchased a new stake in shares of Lantheus in the third quarter worth $439,000. Swedbank AB grew its stake in shares of Lantheus by 53.3% in the fourth quarter. Swedbank AB now owns 1,107,243 shares of the medical equipment provider's stock worth $99,054,000 after acquiring an additional 385,000 shares during the last quarter. Finally, Keybank National Association OH purchased a new stake in shares of Lantheus in the fourth quarter worth $27,526,000. 99.06% of the stock is owned by hedge funds and other institutional investors.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California's 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027. Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California's 31st Congressional District. He declared candidacy for the 2026 election. Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor's degree in political science from George Washington University in 1994, a master's in business administration from Regis University in 2002, and a master's degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.